Our findings demonstrate the SphK2/CERT axis as a novel therapeutic target for NAFLD-HCC, although the intricate role of these coupled lipid regulators in different cancer contexts warrants further investigation. The gene discussed is CERT1; the disease is metabolic dysfunction-associated steatotic liver disease.